Voyager Therapeutics (VYGR) Misses Q2 EPS by 4c

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.57), $0.04 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $9.5 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Krait Critical Minerals closes $1.22M first tranche of placement
• Boeing and Bell Boeing receive defense contracts totaling $56.4M